SG11201509835RA - (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidine-2,4-dione and drug containing same - Google Patents
(+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidine-2,4-dione and drug containing sameInfo
- Publication number
- SG11201509835RA SG11201509835RA SG11201509835RA SG11201509835RA SG11201509835RA SG 11201509835R A SG11201509835R A SG 11201509835RA SG 11201509835R A SG11201509835R A SG 11201509835RA SG 11201509835R A SG11201509835R A SG 11201509835RA SG 11201509835R A SG11201509835R A SG 11201509835RA
- Authority
- SG
- Singapore
- Prior art keywords
- methyl
- oxopyridin
- imidazolidine
- difluorophenyl
- dione
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013120692 | 2013-06-07 | ||
| PCT/JP2014/065060 WO2014196623A1 (en) | 2013-06-07 | 2014-06-06 | (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidine-2,4-dione and drug containing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509835RA true SG11201509835RA (en) | 2015-12-30 |
Family
ID=52008252
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509835RA SG11201509835RA (en) | 2013-06-07 | 2014-06-06 | (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidine-2,4-dione and drug containing same |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9518041B2 (en) |
| EP (1) | EP3006437B1 (en) |
| JP (1) | JP6247689B2 (en) |
| KR (2) | KR102321814B1 (en) |
| CN (1) | CN105531270B (en) |
| AU (1) | AU2014275835B2 (en) |
| BR (1) | BR112015030490B1 (en) |
| CA (1) | CA2913858C (en) |
| ES (1) | ES2818931T3 (en) |
| HK (1) | HK1221219A1 (en) |
| IL (1) | IL242861B (en) |
| MX (1) | MX364780B (en) |
| MY (1) | MY173075A (en) |
| NZ (1) | NZ714700A (en) |
| PH (1) | PH12015502661A1 (en) |
| RU (1) | RU2668072C2 (en) |
| SG (1) | SG11201509835RA (en) |
| TW (1) | TWI636782B (en) |
| WO (1) | WO2014196623A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2014196624A1 (en) * | 2013-06-07 | 2017-02-23 | 科研製薬株式会社 | Composition for maintaining platelet function |
| CN107304205B (en) * | 2016-04-22 | 2020-10-30 | 上海医药工业研究院 | Maravirenz intermediate and preparation method thereof |
| CN109803961B (en) * | 2016-09-23 | 2021-03-23 | 科研制药株式会社 | Process for producing (R) -5- (3, 4-difluorophenyl) -5- [ (3-methyl-2-oxopyridin-1 (2H) -yl) methyl ] imidazolidine-2, 4-dione and intermediate for production thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03008180A (en) * | 2001-03-15 | 2003-12-12 | Astrazeneca Ab | Metalloproteinase inhibitors. |
| DE60230781D1 (en) | 2001-09-07 | 2009-02-26 | Kaken Pharma Co Ltd | Reverse hydroxamsäurederivate |
| GB0221246D0 (en) | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
| AU2003282920A1 (en) | 2002-10-04 | 2004-05-04 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) |
| US7132432B2 (en) | 2003-06-05 | 2006-11-07 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) |
| GB0405101D0 (en) | 2004-03-06 | 2004-04-07 | Astrazeneca Ab | Compounds |
| US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| AU2005275213A1 (en) | 2004-07-16 | 2006-02-23 | Schering Corporation | Hydantoin derivatives for the treatment of inflammatory disorders |
| US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| PE20071240A1 (en) | 2006-01-17 | 2008-01-14 | Schering Corp | HYDANTOIN-DERIVED COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS |
| MX2010014231A (en) * | 2008-06-17 | 2011-03-21 | Astellas Pharma Inc | Pyridone compound. |
| US8450355B2 (en) | 2008-09-24 | 2013-05-28 | Merck Sharp & Dohme Corp. | Compounds for the treatment of inflammatory diseases |
| US8569336B2 (en) * | 2008-11-10 | 2013-10-29 | Ling Tong | Compounds for the treatment of inflammatory disorders |
| LT2789607T (en) * | 2011-12-09 | 2018-03-26 | Kaken Pharmaceutical Co., Ltd. | Pyridone derivative and medicine containing same |
-
2014
- 2014-06-06 CN CN201480032095.3A patent/CN105531270B/en active Active
- 2014-06-06 AU AU2014275835A patent/AU2014275835B2/en active Active
- 2014-06-06 EP EP14806840.6A patent/EP3006437B1/en active Active
- 2014-06-06 US US14/895,768 patent/US9518041B2/en active Active
- 2014-06-06 ES ES14806840T patent/ES2818931T3/en active Active
- 2014-06-06 WO PCT/JP2014/065060 patent/WO2014196623A1/en active Application Filing
- 2014-06-06 KR KR1020157034539A patent/KR102321814B1/en active IP Right Grant
- 2014-06-06 RU RU2015156531A patent/RU2668072C2/en active
- 2014-06-06 CA CA2913858A patent/CA2913858C/en active Active
- 2014-06-06 MX MX2015016828A patent/MX364780B/en active IP Right Grant
- 2014-06-06 KR KR1020217035383A patent/KR102379801B1/en active IP Right Grant
- 2014-06-06 MY MYPI2015704380A patent/MY173075A/en unknown
- 2014-06-06 BR BR112015030490-7A patent/BR112015030490B1/en active IP Right Grant
- 2014-06-06 TW TW103119743A patent/TWI636782B/en active
- 2014-06-06 JP JP2015521499A patent/JP6247689B2/en active Active
- 2014-06-06 SG SG11201509835RA patent/SG11201509835RA/en unknown
- 2014-06-06 NZ NZ714700A patent/NZ714700A/en unknown
-
2015
- 2015-11-27 PH PH12015502661A patent/PH12015502661A1/en unknown
- 2015-11-30 IL IL242861A patent/IL242861B/en active IP Right Grant
-
2016
- 2016-08-04 HK HK16109328.6A patent/HK1221219A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181392T1 (en) | Heterocyclic compounds and uses thereof | |
| HK1223351A1 (en) | Heterocyclic compounds and uses thereof | |
| IL244818A0 (en) | Heterocyclic compounds and uses thereof | |
| EP3076878A4 (en) | Surfboard accessory for surfboard retention and medical emergencies | |
| IL233482A0 (en) | Stabilized formulations containing anti-ang2 antibodies | |
| ZA201603934B (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin | |
| ZA201508118B (en) | Herbicidally active (alkynyl-phenyl)-substituted cyclic dione compounds and derivatives thereof | |
| HK1221215A1 (en) | Zxc4-alkynyl imidazole derivative and medicine comprising same as active ingredient 4- | |
| ZA201603272B (en) | Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin | |
| PL2634174T3 (en) | Nitrogen-containing heterocyclic derivate having 2-imino group and pest control agent including the same | |
| EP3088372A4 (en) | Zirconia sintered body and use thereof | |
| IL240875A0 (en) | Heterocyclic compounds and pharmaceutical compositions containing them | |
| HK1221219A1 (en) | ()-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)- yl)methyl]imidazolidine-2,4-dione and drug containing same ()-5-(34-)-5-[(3--2--1(2h)-)]-24- | |
| EP3006420A4 (en) | Ceramic sintered body, and anticorrosion member, filter and antihalation member formed using same | |
| SI2970210T1 (en) | Pyrazolylbenzo(d)imidazole derivatives | |
| IL265481B (en) | Method for producing (r)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidin-2,4-dione and intermediate for producing same | |
| HK1222655A1 (en) | Novel salt of 3-[(3-[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]met hylene-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1, 3-thiazolidine- 2,4-dione, preparation thereof and formulations containing same 3-[(3-[4-(4-)-1h--2-]-2--23--1h- -5-)]-13--24- | |
| HK1223834A1 (en) | Biologically active insulin derivatives | |
| TH1501007248A (en) | (+)-5-(3,4difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl] I Midazolidine-2,4-dione and drugs containing the same | |
| EP3089974A4 (en) | Novel imidazolidine-2,4-dione derivatives | |
| GB201610823D0 (en) | Heterocyclic compounds and medical uses | |
| EP3089975A4 (en) | Novel imidazolidine-2, 4-dione derivatives | |
| ZA201404909B (en) | Stabilized formulations containing anti-ang2 antibodies |